#USA #Class Action #San Francisco #Hagens Berman #Embecta Corp

Hagens Berman Investigates Embecta Corp.

Hagens Berman, a respected law firm specializing in shareholder rights, has announced its investigation into Embecta Corp. (NASDAQ: EMBC). The inquiry is in response to serious allegations of violations of federal securities laws following the filing of a class action lawsuit in the U.S. District Court for the District of New Jersey. This lawsuit claims that Embecta misled investors about the commercial stability of its insulin pen needle business, a core aspect of its operations.

Background of the Class Action

The investigation stems from the assertion that Embecta’s management provided false assurances regarding the health and performance of its insulin pen needle segment. During the period from November 25, 2025, to May 4, 2026, Embecta reportedly informed its investors that its pen needle portfolio was characterized by stability, resilience, and reliability. These statements are now under scrutiny as plaintiffs allege they were misleading. The lawsuit contends that the company was actually experiencing a significant decline in market share, particularly with a key customer, and was aware of a general drop in sales within the retail channel. Despite this knowledge, Embecta continued to uphold a positive financial outlook.

On May 5, 2026, the truth was revealed when Embecta made its second-quarter fiscal 2026 financial announcement, reporting a dramatic revenue fall. This announcement contradicted prior reassurances given to investors, revealing dire conditions affecting the U.S. pen needle market that the company had previously downplayed. Compounding this bad news, Embecta also slashed its adjusted earnings-per-share guidance for the full year of 2026 by a staggering 43%, coupled with a drastic reduction in its quarterly dividend from $0.15 to a mere $0.01 per share.

Impact on Investors

The response from the market was swift and severe; Embecta's stock saw a dramatic drop of almost 58% on the day of the announcement, reflecting the investor panic and realization of the misleading nature of earlier communications. Such significant volatility raises concerns about the integrity of the company’s prior disclosures and the potential repercussions for affected investors.

Reed Kathrein, the lead partner at Hagens Berman overseeing the investigation, articulated the firm’s commitment to determining whether Embecta's prior assurances were indeed deceptive, especially given the recent stark admission of revenue declines aligned with the claims made in the lawsuit.

How Can Investors React?

Hagens Berman encourages Embecta investors who have experienced substantial losses to reach out to them for potential assistance. Furthermore, potential whistleblowers with relevant information related to Embecta’s operations are advised to consider the SEC Whistleblower program, which could provide incentives for reporting original information pertinent to the investigation. Whistleblowers could earn rewards of up to 30% of any successful SEC recoveries resulting from shared information.

About Hagens Berman

Established as a powerful advocate for investors, Hagens Berman dedicates its resources to ensure corporate accountability and justice for shareholders. The firm boasts a successful track record, having secured over $2.9 billion for its clients in similar litigations. For more information on this ongoing investigation and other relevant updates, investors can visit Hagens Berman’s website or follow them for real-time news updates.

In the wake of this troubling investigation, affected investors are encouraged to document their losses and consider the steps necessary to protect their rights.

For further assistance, the legal team can be reached via email at [email protected] or by phone at 844-916-0895.